Welcome to our dedicated page for HEALTHWAREHOUSE.COM news (Ticker: $HEWA), a resource for investors and traders seeking the latest updates and insights on HEALTHWAREHOUSE.COM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HEALTHWAREHOUSE.COM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HEALTHWAREHOUSE.COM's position in the market.
HealthWarehouse.com, Inc. (HEWA) reported a 3% decrease in net sales totaling $5.1 million for the first quarter of 2024 compared to the same period in 2023. The company reported a net loss of $252,412 and positive EBITDA of $89,723 for the quarter. Despite the decline in revenue, HealthWarehouse.com experienced a 7% growth in direct-to-consumer prescription sales. The company remains optimistic about future sales growth in 2024, focusing on new partnerships and recovering lost sales due to supply issues. HealthWarehouse.com continues to invest in technology to enhance operational efficiency and customer experience. Gross profit decreased by 10.0% due to lower sales and margins. Operating expenses decreased by 8.8% primarily in advertising, marketing, shipping, and salaries, offset by increased expenses in software engineering and stock-based compensation. The company reported a net loss of $252,000 for the quarter, an improvement from the previous year, and an Adjusted EBITDA of $90,000.